EP3160459A1 - Neue mineralzusammensetzung - Google Patents

Neue mineralzusammensetzung

Info

Publication number
EP3160459A1
EP3160459A1 EP15736059.5A EP15736059A EP3160459A1 EP 3160459 A1 EP3160459 A1 EP 3160459A1 EP 15736059 A EP15736059 A EP 15736059A EP 3160459 A1 EP3160459 A1 EP 3160459A1
Authority
EP
European Patent Office
Prior art keywords
mineral composition
magnesium
composition according
depression
taurine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15736059.5A
Other languages
English (en)
French (fr)
Inventor
Eduard Antonius Joannes Arnoldussen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dedraf Holding BV
Original Assignee
Dedraf Holding BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dedraf Holding BV filed Critical Dedraf Holding BV
Publication of EP3160459A1 publication Critical patent/EP3160459A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the invention relates to the field of therapies for and prevention of mental disorders, more particularly therapies for depression, burn-out and cognitive disorders, and more specifically for a new mineral composition useful in such therapies.
  • depressive will have symptoms that may be considered to be a pre-stage of depression. Especially in the elderly, depression is often not recognized, but depression related suicide is manifest in aged people. Cognitive impairment is among the classic features of depression, such as e.g. major depressive disorder. Cognitive disorders may to some extent be secondary to depression in the sense that an improvement in the depressive state will also lead to an improvement of the cognitive impairment.
  • Depression is a condition which has links to may other conditions.
  • High blood pressure, high cholesterol levels, diabetes, osteoporosis, asthma, atherosclerosis, arthritis or cardiovascular diseases have a high comorbidity figure with depression.
  • all kinds of psychic disorders such as cognitive deficits, anxiety, ADHD, Alzheimer's disease, dementia and stress disorders are often found together with depression.
  • Magnesium deficiency will accelerate a vicious cycle and amplify the effects of chronic stress, leading to more anxiety, irritability, fatigue and insomnia— many of the symptoms of adrenal exhaustion— as well as to hypertension and heart pains— symptoms of heart disease.
  • Magnesium is utilized by the body for all sorts of detoxification pathways and is necessary for the neutralization of toxins, overly acidic conditions that arise in the body, and for protection from heavy metals. It plays a vital role in protecting us from the onslaught of man-made
  • Glutathione an antioxidant normally produced by the body and a detoxifier of mercury, lead and arsenic among others, requires magnesium for its synthesis.
  • a deficiency of magnesium increases free radical generation in the body and "causes glutathione loss, which is not affordable because glutathione helps to defend the body against damage from cigarette smoking, exposure to radiation, cancer chemotherapy, and toxins such as alcohol and just about everything else.
  • Serotonin the "feel good” hormone, requires magnesium in its delicate balance of release and reception by cells in the brain. Only when adequate levels are present can we enjoy mental and emotional equilibrium. A recent
  • the present inventors found that a mineral composition comprising magnesium glycinate, zinc glycinate and selenium methionine is effective in the prevention and/or treatment of depression and various other psychic and physiologic disorder.
  • the mineral composition further comprises a chromium compound, preferably as chromium picolinate or chromium nicotinate. More preferably, the composition also comprises taurine and even more preferably vitamin B6.
  • the mineral composition comprises > 200 mg
  • the composition also comprises > 0.2 mg chromium picolinate or > 0.2 mg chromium nicotinate and/or > 250 mg taurine, preferably the amount of magnesium glycinate is > 400 mg, more preferably >500 mg, while preferably the amount of zinc glycinate is >4 mg, more preferably >5 mg.
  • composition comprises minerals in the following amounts (+/- 5%, preferably +/- 1%): - magnesium glycinate 625 mg
  • the inventors have found that the mineral composition, when dosed in a therapeutic effective dose is effective for the prevention and/or treatment of depression and various other psychic and physiologic disorder.
  • the mineral compositions according to the present invention can be used in therapy of disorders such as cognitive impairment, depression, burn-out, ADHD, autism, memory loss, Alzheimer's disease, dementia, migraine, loss of IQ, craving for drugs or nicotine, post-menstrual syndrome or of post-traumatic stress disorder.
  • the mineral composition according to the present invention can also be used in the therapy of disorders such as diabetes, osteoporosis, fatigue, asthma, high blood pressure, allergic diseases such as hay fever, eczema, muscular spasm, conditions associated with high cholesterol levels, and heart and vascular diseases.
  • disorders such as diabetes, osteoporosis, fatigue, asthma, high blood pressure, allergic diseases such as hay fever, eczema, muscular spasm, conditions associated with high cholesterol levels, and heart and vascular diseases.
  • the mineral composition can be used in a method for treatment or prevention of cognitive impairment, depression, burn-out, ADHD, autism, memory loss, Alzheimer's disease, dementia, migraine, loss of IQ, craving for drugs or nicotine, post-menstrual syndrome or of post-traumatic stress disorder by treating a subject in need thereof with a mineral composition according to the present invention.
  • the mineral composition can be used in a method for treatment or prevention of diabetes, osteoporosis, fatigue, asthma, allergic diseases such as hay fever, eczema, muscular spasm, conditions associated with high cholesterol levels, and heart and vascular diseases, high blood pressure by treating a subject in need thereof with a mineral composition according to the present invention.
  • the effectiveness of the treatment or prevention according to the present invention can be determined by regularly measuring changes in biomarker values wherein said biomarkers are chosen from substance P, aldosterone, thromboxane, endothelin 1, EGF, vitamin D and telomerase. A full description of these markers can be found in PCT/NL2014/050054. Further biomarkers for use in such a method to determine the effectiveness of the treatment or prevention may be all enzymes that use Mg 2+ as a cofactor.
  • composition comprising specific salts of magnesium, chromium and selenium is effective in the prevention and/or treatment of depression and various other psychic and physiologic disorders.
  • magnesium is often provide in the form of magnesium oxide. It has been submitted that magnesium oxide is poorly absorbed by the body in contrast to e.g. magnesium citrate (Lindberg, J.S. et al., 1990, J. Am. Coll. Nutr. 9:48-55). The recommended dietary allowance for magnesium is 350 mg/day for a male adult and 280 mg/day for a female. However, for therapeutic purposes higher dosages are needed, but the therapeutic window for magnesium is wide and rarely side- effects of magnesium intoxication are found (Saris, N.-E. et al., 2000, Clin. Chim. Acta, 294: 1-26).
  • magnesium oxide In order to provide for a sufficient therapeutic dose, it is recommended not to use magnesium oxide. Therefor, in the present mineral composition the glycinate salt of magnesium is used. Because salts based on amino acids are much better-tolerated by the digestive system and do not have the side-effects of the older compounds used. Since magnesium glycinate is a relatively large molecule, it is not standardly included in multi-prep ar ations .
  • magnesium preparations seem to be a valuable addition to the pharmacological armamentarium for management of depression. Apart from being administered as components of dietary supplements, magnesium preparations also perceived as the effective agents in treatment of migraine, alcoholism, asthma, heart diseases, arrhythmias, renal calcium stones, premenstrual tension syndrome etc. Magnesium preparations have an essential place in homeopathy as a remedy for a range of mental health problems. (Serefko, A., et al., 2013, Pharmacol. Rep.
  • Zinc is an NMDA receptor antagonist and thus inhibits the transfer of stimuli and loss of magnesium. Zinc deficiency leads to decreased zinc in the nerve synapse, which results in an increase in the NMDA receptors. These receptors respond to glutamate, an excitatory neurotransmitter that can be responsible for toxic effects in the brain if there is too much. At the same time, the inhibitory (in this case, neuroprotective) neurotransmitter GABA is decreased, along with BDNF and another nerve growth factor, NGF. The glutamate level in the synapse is higher, so calcium mediated stimulation of the nerves is primed. This same mechanism is thought (in acute vs chronic and in differing areas of the brain) to be responsible for seizures, migraines, dementia, anxiety, depression, and bipolar disorder (and is why
  • GABA receptor modulators such as valium and anti-seizure medicines
  • zinc supplementation (together with normal medication of serotonin reuptake inhibitors) significantly improves the condition of patients with major depression (Ranibar, E., et al., 2013, Iran. J. Psychiatry 8:73-79).
  • Selenium methionine (or selenomethionine) also has been abundantly used in food supplements in order to achieve the daily
  • the mineral composition of the present invention may optionally comprise taurine and/or chromium picolinate.
  • the amino acid taurine is known for its many advantageous effects, especially on depression, anxiety, fatigue, etc. It generally is advocated as an anti-stress cure, because taurine calms the nervous system by
  • taurine By helping to raise GABA levels, taurine will allow the body to manage anxiety. Taurine is stored in the gallbladder in bile, and it helps the body digest food, particularly fats. Taurine helps the body metabolize fat, making it essential for energy production and a lean physique. But, it is also necessary for many aspects of health because "good" fats play a role in the health of every cell in the body. Partly because of this effect, taurine is a well known supplement for preventing diabetes and improving insulin sensitivity. Taurine makes the cells more sensitive to insulin binding and glucose uptake by multiple mechanisms. First, taurine has an anorexigenic effect on the hypothalamus gland, meaning that it minimizes feelings of hunger by improving energy production and metabolism.
  • taurine enhances the role of insulin in the control of food intake and helps stall body fat gain (Solon, C.S. et al., 2012, Amino Acids 42:2403- 2410). Because of the fact that insulin has a role in the storage of magnesium in the cell, addition of taurine enhances the effects of
  • Taurine has many other proven therapeutic effects: it is one of the main nutrients for the heart musculature and it could help against heart rhythm disorders. It has also been proved to be effective against high blood pressure by inhibiting the antidiuretic hormone. It is also one of the important components of the eye lens and retina.
  • taurine also facilitates the intracellular availability of magnesium and thus the therapeutic effects of magnesium.
  • the organism appears to stimulate taurine mobilization. This compensatory action is known to occur e.g. during migraine.
  • the taurine in the mineral composition of the present invention may also be present as the magnesium salt, i.e. as magnesium taurate.
  • Chromium picolinate is mainly provided to inhibit chromium deficiency, but it is also heavily used for its beneficial effects against insulin resistance, diabetes type II and metabolic syndrome.
  • Insulin resistance is a physiological condition in which cells fail to respond to the normal actions of the hormone insulin.
  • the picolinate salt is more effective to achieve absorption of chromium than other salts.
  • the picolinate salt may have some adverse effects (especially cancer promoting effects: Stearns, D.M. et al., 1995, FASEB J. 9: 1643-1648), and for this reason the use of the nicotinate salt of chromium has been proposed as an alternative, but this has not yet been tested as frequently as the picolinate salt.
  • Insulin resistance also has the effect that magnesium no longer can be stored in the cells. Accordingly, addition of chromium to the mineral composition of the invention has the effect that magnesium still can be taken up and stored in the cell.
  • the invention may also comprise mineral compositions where additional minerals, vitamins or salts have been added. Such additions are - of course - only beneficial if they do not interfere with the above indicated effects of magnesium, zinc, chromium, selenium and taurine. In this case, it should be repeated that it would not be advisable to increase calcium uptake (e.g. by addition of Ca-salts in the present mineral composition), because calcium negatively affects the uptake of magnesium and zinc.
  • treatment and “treating” refer to any and all uses which remedy a condition or disease or symptoms thereof, prevent the establishment of a condition or disease or symptoms thereof, or otherwise prevent or hinder or reverse the progression of a condition or disease or other undesirable symptoms in any way whatsoever.
  • the term "therapeutically effective amount” includes within its meaning a non-toxic amount of each of the indicated compounds, alone or in combination, sufficient to provide the desired therapeutic effect. The exact amount will vary from subject to subject depending on the age of the subject, their general health, the severity of the disorder being treated and the mode of administration. It is therefore not possible to specify an exact “therapeutically effective amount", however one skilled in the art would be capable of determining a
  • the present invention relates to a method for the treatment of depression and cognitive deficits or cognitive impairment, said method comprising the administration of a mineral composition of the present invention to a patient in need thereof.
  • Cognitive deficits include a decline in cognitive functions or cognitive domains, e.g. working memory, attention and vigilance, verbal learning and memory, visual learning and memory, reasoning and problem solving e.g. executive function, speed of processing and/or social cognition.
  • cognitive deficits or cognitive impairment may indicate deficits in attention, disorganized thinking, slow thinking, difficulty in understanding, poor concentration, impairment of problem solving, poor memory, difficulties in expressing thoughts and/or difficulties in integrating thoughts, feelings and behavior, or difficulties in extinction of irrelevant thoughts.
  • cognitive deficits and
  • Cognitive impairment are intended to indicate the same and are used interchangeably. Cognitive impairment is a particularly important consideration in the elderly. Cognitive impairment normally increases with age, and further with depression.
  • the patient to be treated for cognitive impairment is elderly, and in particular elderly with depression.
  • next to patients suffering from psychological disorders, such as depression, and/or cognitive disorders also patients suffering from various physiological diseases may benefit of treatment with the mineral composition according to the invention.
  • diseases are diabetes, insulin resistance, osteoporosis, vascular diseases, high blood pressure, rheumatoid arthritis, muscular spasms, fatigue, premenstrual stress syndrome, allergic rhinitis, eczema, allergic diseases, such as hay fever, COPD and asthma.
  • the mineral composition of the present invention may be administered in any acceptable way. Preferably, administration is dealt with orally or topically,
  • compositions may be packed in e.g. gelatin capsules or may be tableted in the form of tablets or may be given in liquid compositions.
  • active compound may be administered with excipients and e.g. used in the form of powders, sachets, tablets, pills, pastilles or capsules.
  • compositions may be prepared by conventional means with
  • binding agents e.g., binding agents
  • pregelatinised maize starch tragacanth gum, gelatine, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • fillers e.g. lactose, microcrystalline cellulose, mannitol or calcium hydrogen phosphate
  • lubricants e.g.
  • Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g.
  • sorbitol syrup cellulose derivatives or hydrogenated edible fats
  • emulsifying agents e.g. lecithin or acacia
  • non- aqueous vehicles e.g.
  • preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.
  • Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
  • compositions may take the form of tablets or lozenges formulated in conventional manner.
  • compositions may be in the form of dispersions (solutions, suspensions) in an aqueous or oil solution or dispersed into an emulsion, wherein said emulsion may be water-in-oil, oil- in-water or any double emulsion.
  • the formulation may take the form of an oil, a creme, an ointment, a lotion, a paste, a gel, a jelly, a foam, a spray, a (dermal) patch,
  • formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.
  • the capsule When dosing is in the form of a capsule, the capsule may comprise apart from the elements mentioned above a liquid carrier such as an oil. Dosage form may further be provided with coatings of sugar, shellac or other agents.
  • the components of the pharmaceutical composition are preferably chosen such that they do not reduce the desired working of the active compound.
  • compositions can further comprise flavoring sweetening, coloring and/or preservative agents.
  • a mineral composition according to the invention or a
  • pharmaceutically acceptable salt thereof may also be administered in the form of e.g. an elixir, a suspension, a syrup, a waffle or a chewing gum.
  • the total of active minerals and further therapeutically active compounds, such as the amino acid taurine will be present in an amount of from 0.01 to 99.9 % by weight, preferably from 10 to 90 wt.%, and more preferably from 30 to 80 wt.%.
  • the present invention further relates to a method for the preparation of a mineral composition for use as medicament, comprising processing or incorporating a mineral composition according to the invention, as an active substance, together with a pharmaceutically acceptable carrier in a pharmaceutical composition.
  • the preparation of a pharmaceutical composition may very suitably occur by mixing all separate ingredients such as fillers, binders, lubricants and optionally other excipients together with one or more of the minerals and /or taurine, and processing the mixture obtained to a pharmaceutical preparation.
  • PCT/NL2014/050054 may be used. In order to obtain a good overview of the improvement of the depression over the treatment time a regular assay as described in PCT/NL2014/050054 should be performed.
  • Monitoring of the treatment of cognitive disorders may be performed by regularly performing questionnaires as are described in the DSM manual, or by using the Alzheimer Questionnaire (Malek-Ahmadi, M. et al., 2012, Age Ageing 41:396-399) or other comparable diagnostic systems (such as the 4-item Abbreviated Mental Test described in. Schofield, I. et al., 2010, Eur. J. Emerg. Med. 17:340-342).
  • pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
  • a solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
  • the carrier is a finely divided solid which is in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets preferably contain from five or ten to about seventy percent of the active compound.
  • Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
  • the term "preparation” is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it.
  • cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.
  • Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water-propylene glycol solutions.
  • the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents.
  • the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilisation from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
  • Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilizing and thickening agents, as desired.
  • Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium
  • liquid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration.
  • liquid forms include solutions, suspensions, and emulsions.
  • preparations may contain, in addition to the active component, colorants, flavours, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
  • the pharmaceutical preparations are preferably in unit dosage forms.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • magnesium glycinate >200 mg, pref. >400 mg, more pref. >500 mg zinc glycinate > 2 mg, pref. >4 mg, more pref. >5 mg
  • composition may also additionally comprises
  • taurine 300 mg The amounts here are indications and may differ + or - 5%, more preferably +/- 1%.
  • composition as defined above may additionally comprise magnesium stearate as lubricant > 5mg and silicium dioxide as anticoagulant > 5 mg.
  • Example 1 Preparation of a mineral composition.
  • silicium dioxide as SYLOID® AL-1 FP from W.R. Crace&Co.-Conn
  • Chromium picolinate (minimally 12% chromium) 6.1
  • Zinc Glycinate Chelate (minimally 20% Zn) 8.3 Selenomethionine (5000 pg/g Se) 1.8
  • Crystalline microcellulose (Microcel MCC 101) 531.7
  • the tablets were coated in a normal tablet coating machine (FC 39 from NR Group, 97200 tablets per batch) with the following composition (amounts average per tablet):
  • depression may be treated by oral administration of the mineral composition.

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP15736059.5A 2014-06-24 2015-06-24 Neue mineralzusammensetzung Withdrawn EP3160459A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2013055 2014-06-24
PCT/NL2015/050460 WO2015199537A1 (en) 2014-06-24 2015-06-24 New mineral composition

Publications (1)

Publication Number Publication Date
EP3160459A1 true EP3160459A1 (de) 2017-05-03

Family

ID=52014299

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15736059.5A Withdrawn EP3160459A1 (de) 2014-06-24 2015-06-24 Neue mineralzusammensetzung

Country Status (3)

Country Link
EP (1) EP3160459A1 (de)
EA (1) EA201790017A1 (de)
WO (1) WO2015199537A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1025644B1 (fr) * 2017-10-13 2019-05-15 Synapharm Industrial Synthesis Compose pour le traitement d'une maladie ou d'un trouble du systeme nerveux central chez un sujet en stimulant et/ou en restaurant la plasticite neuronale

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206895A1 (en) * 1998-11-13 2003-11-06 Sigma-Tau Healthscience S.P.A. Antioxidant composition comprising propionyl L-carnitine and a flavonoid against throm-bosis and atherosclerosis
DK1163904T3 (da) * 2000-06-16 2006-08-14 Matthias Dr Med Rath Sammensætning til forebyggelse af glat muskelsygdom, der omfatter ascorbat, arginin og magnesium
UA77660C2 (en) * 2000-10-03 2007-01-15 Compositions and methods for reducing plasma lipoprotein a level in human
US20040001817A1 (en) * 2002-05-14 2004-01-01 Giampapa Vincent C. Anti-aging nutritional supplement
US7034012B2 (en) * 2002-11-01 2006-04-25 Matthias Rath Composition and method for prevention and treatment of arrhythmias
WO2005023274A1 (en) * 2003-09-05 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
CA2788315A1 (en) * 2010-01-26 2011-08-04 Ridge Diagnostics, Inc. Multiple biomarker panels to stratify disease severity and monitor treatment of depression
NL2010214C2 (en) * 2013-01-31 2014-08-04 Brainlabs B V Novel diagnostic method for diagnosing depression and monitoring therapy effectiveness.

Also Published As

Publication number Publication date
EA201790017A1 (ru) 2017-06-30
WO2015199537A1 (en) 2015-12-30

Similar Documents

Publication Publication Date Title
US11116779B2 (en) Methods for modulating corticosterone levels in psychologically stressed individuals
EP2708147B1 (de) Verfahren zur Erhöhung der Gehirnfunktion unter Verwendung von 2-Fucosyl-Lactose
US9326956B2 (en) Methods for improving brain development and cognitive function using beta-hydroxy-beta methylbutyrate
US20200129463A1 (en) Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans
EP2214518A1 (de) Stoffwechselförderungstherapie
AU2005244816B2 (en) Uridine effects on dopamine release
EP2986163B1 (de) Nahrungsmittelprodukte mit calcium beta-hydroxy-beta-methylbutyrat, caseinphosphopeptide und proteine
CN111526879A (zh) 用于减少或预防疲劳和/或改善注意力或专注力的一种或多种hmo
Kumar Nutrients and neurology
US20230364042A1 (en) Administration of beta-hydroxybutyrate and related compounds in humans for the treatment and/or prevention of respiratory illnesses
US20110274791A1 (en) Multivitamin/mineral formulation to combat the effects of environmental stress; improved immunity and improve energy while addressing vitamin and mineral deficiencies without the negative side effects of a mega dose nutritional supplement
WO2015199537A1 (en) New mineral composition
WO1993002682A1 (en) Method and compositions for reducing craving for alcohol and stimulants
US20220362188A1 (en) Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20170123

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170822